The guide supports healthcare professionals with the dosing and administration of LENVIMA® (lenvatinib) in their patients with Endometrial Cancer.
It provides guidance on how and when to take LENVIMA®, dose adjustments, and special warnings and precautions for its use. All of the information included is based on the Summary of Product Characteristics.
Supporting documentation:
LENVIMA® 4 mg hard capsules Summary of Product Characteristics
LENVIMA® 10 mg hard capsules Summary of Product Characteristics
GB-KLE-00105 Date of Preparation April 2023
